Information de reference pour ce titreAccession Number: | 00004227-200201000-00002.
|
Author: | Aalberse, Rob C.; Schuurman, Janine 1
|
Institution: | Department of Immunopathology, CLB and Laboratory for Experimental and Clinical Immunology, Academical Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
|
Title: | IgG4 breaking the rules.[Review]
|
Source: | Immunology. 105(1):9-19, January 2002.
|
Abstract: | Summary: Immunoglobulin G4 (IgG4) antibodies have been known for some time to be functionally monovalent. Recently, the structural basis for this monovalency has been elucidated: the in vivo exchange of IgG half-molecules (one H-plus one L-chain) among IgG4. This process results in bispecific antibodies that in most situations will behave as functionally monovalent antibodies. The structural basis for the abnormal behaviour of IgG4 seems to be largely the result of a single amino acid change relative to human IgG1: the change of a proline in core hinge of IgG1 to serine. This results in a marked shift in the equilibrium between interchain disulphide bridges and intrachain disulphide bridges, which for IgG4 results in 25-75% absence of a covalent interaction between the H-chains. Because of strong non-covalent interactions between the CH3 domains (and possibly also between the CH1 domain and the trans-CH2 domain) IgG4 is a stable four-chain molecule and does not easily exchange half-molecules under standard physiological conditions in vitro. We postulate that the exchange is catalysed in vivo by protein disulphide isomerase (PDI) and/or FcRn (the major histocompatibility complex (MHC)-related Fc receptor) during transit of IgG4 in the endosomal pathway in endothelial cells. Because IgG4 is predominantly expressed under conditions of chronic antigen exposure, the biological relevance of this exchange of half-molecules is that it generates antibodies that are unable to form large immune complexes and therefore have a low potential for inducing immune inflammation. In contrast to monovalent immunoglobulin fragments, these scrambled immunoglobulins have a normal half-life. The significance of the ensuing bispecificity needs further evaluation, because this will be relevant only in situations where high IgG4 responses are found to two unrelated antigens that happen to be present in the body at the same time and place. In this context the significance of IgG4 autoreactivity might have to be re-evaluated. The main function of IgG4, however, is presumably to interfere with immune inflammation induced by complement-fixing antibodies, or, in the case of helminth infection or allergy, by IgE antibodies.
(C) 2002 Blackwell Science Ltd.
|
References: | 1 Angal S, King DJ, Bodmer MW, Turner A, Lawson ADG, Roberts G, Pedley B, Adair JR. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105-8.
2 Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 1997; 6:407-15.
3 Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1-8.
4 Aalberse RC, Van Der Gaag R, Van Leeuwen J. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983; 130:722-6.
5 Van Der Zee JS, Van Swieten P, Aalberse RC. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 1986; 137:3566-71.
6 Schuurman J, Van Ree R, Perdok GJ, Van Doorn HR, Tan KY, Aalberse RC. Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 1999; 97:693-8.
7 Turner MW, Bennich HH, Natvig JB. Pepsin digestion of human G-myeloma proteins of different subclasses. II. Immunochemical investigations of the products of peptic digestion. Clin Exp Immunol 1970; 7:627-40.
8 Petersen JG, Dorrington KJ. An in vitro system for studying the kinetics of interchain disulfide bond formation in immunoglobulin G. J Biol Chem 1974; 249:5633-41.
9 Colcher D, Milenic D, Roselli M et al. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res 1989; 49:1738-45.
10 Tan LK, Shopes RJ, Oi VT, Morrison SL. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci USA 1990; 87:162-6.
11 Norderhaug L, Brekke OH, Bremnes B, Sandin R, Aase A, Michaelsen TE, Sandlie I. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge. Eur J Immunol 1990; 21:2379-84.
12 Padlan EA. Anatomy of the antibody molecule. Mol Immunol 1994; 31:169-217.
13 Burton DR, Gregory L, Jefferis R. Aspects of the molecular structure of IgG subclasses. Monogr Allergy 1986; 19:7-35.
14 King DJ, Adair JR, Angal S, Low DC, Proudfoot KA, Lloyd JC, Bodmer MW, Yarranton GT. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment. Biochem J 1992; 281:317-23.
15 Chivers PT, Prehoda KE, Raines RT. The CXXC motif: a rheostat in the active site. Biochemistry 1997; 36:4061-6.
16 Alphey MS, Leonard GA, Gourley DG, Tetaud E, Fairlamb AH, Hunter WN. The high resolution crystal structure of recombinant Crithidia fasciculata tryparedoxin-I. J Biol Chem 1999; 274:25613-22.
17 Guddat LW, Bardwell JC, Glockshuber R, Huber-Wunderlich M, Zander T, Martin JL. Structural analysis of three His32 mutants of DsbA: support for an electrostatic role of His32 in DsbA stability. Protein Sci 1997; 6:1893-900.
18 Guddat LW, Bardwell JC, Martin JL. Crystal structures of reduced and oxidized DsbA: investigation of domain motion and thiolate stabilization. Structure 1998; 6:757-67.
19 Wunsch E, Moroder L, Gohring-Romani S, Musiol HJ, Gohring W, Bovermann G. Synthesis of the bis-cystinyl-fragment 225-232/225'-232' of the human IgGl hinge region. Int J Pept Protein Res 1988; 32:368-83.
20 Kessler H, Mronga S, Muller G, Moroder L, Huber R. Conformational analysis of a IgG1 hinge peptide derivative in solution determined by NMR spectroscopy and refined by restrained molecular dynamics simulations. Biopolymers 1991; 31:1189-204.
21 Wunsch E, Moroder L, Gohring-Romani S, Musiol HJ, Gohring W, Scharf R. Fully synthetic immunogens. Part II. Studies on parallel dimerization of the human IgG1 hinge-fragment 225-232 with N- or C-terminal gastrin related extensions. Int J Pept Protein Res 1991; 37:61-71.
22 Dall'Acqua W, Simon AL, Mulkerrin MG, Carter P. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. Biochemistry 1998; 37:9266-73.
23 Holm L, Sander C. Protein structure comparison by alignment of distance matrices. J Mol Biol 1993; 233:123-38.
24 Aalberse RC. Structural biology of allergens. J Allergy Clin Immunol 2000; 106:228-38.
25 Corper AL, Sohi MK, Bonagura VR et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997; 4:374-81.
26 Isenman DE, Dorrington KJ, Painter RH. The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. J Immunol 1975; 114:1726-9.
27 Dorrington KJ, Isenman DE, Klein MH, Painter RH, Romans DG. Biological role of IgG hinge region. Nature 1985; 314:500.
28 Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, VT. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 1997; 7:1989-94.
29 Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol 1988; 159:3372-82.
30 Gregory L, Davis KG, Sheth B, Boyd J, Jefferis R, Nave C, Burton DR. The solution conformations of the subclasses of human IgG deduced from sedimentation and small angle X-ray scattering studies. Mol Immunol 1987; 24:821-9.
31 Phillips ML, Tao MH, Morrison SL, Schumaker VN. Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: Electron microscopic and hydrodynamic characterization. Mol Immunol 1994; 31:1201-10.
32 Horgan C, Brown K, Pincus SH. Studies on antigen binding by intact and hinge-deleted chimeric antibodies. J Immunol 1993; 150:5400-7.
33 Michaelsen TE. Alteration of the conformation of human IgG subclasses by reduction of the hinge S-S bonds. Mol Immunol 1988; 25:639-46.
34 Loseva OI, Tischenko VM, Olsovska Z, Franek F, Zav'Yalov VP. Correlation of the character of intramolecular melting with digestibility by pepsin in precipitating and non-precipitating pig anti-Dnp antibodies. Mol Immunol 1986; 23:743-6.
35 Wide L. Solid-phase antigen systems. In: Kirkham KE, Hunter WM, eds. Radioimmunoassay Methods. Edinburgh: E & S Livingstone, 1970:405-11.
36 Aalberse RC, Dieges PH, Knul-Bretlova V, Vooren P, Aalbers M, Van Leeuwen J. IgG4 as a blocking antibody. In: Halpern GM, ed. Clinical Reviews in Allergy, Vol. 1. New York: Elsevier Biomedical, 1983:289-302.
37 Aalberse RC, Van Der Zee JS, Vlug A. IgG4 antibodies in atopic allergy. Lab Man 1985; 23:19-32.
38 Van Ree R, Stapel SO, Aalberse RC. Reverse-sandwich ELISA may underestimate antibody titers. J Allergy Clin Immunol 1989; 84:562-3.
39 Van Der Giessen M, Homan WL, Van Kernebeek G, Aalberse RC, Dieges PH. Subclass typing of IgG antibodies formed by grasspollen-allergic patients during immunotherapy. Int Arch Allergy Appl Immunol 1976; 50:625-40.
40 Aalberse J, Perzanowsky MS, Platts-Mills TAE, Aalberse RC. Precipitating and precipitation-inhibiting (=IgG4) antibodies to Fel d 1 in atopic subjects. J Allergy Clin Immunol 2001; 107:182S.
41 Margni RA, Borel IM. Paradoxical behavior of asymmetric IgG antibodies. Immunol Rev 1998; 163:77-87.
42 Raina S, Missiakas D. Making and breaking disulfide bonds. Annu Rev Microbiol 1997; 51:179-202.
43 Burgess JK, Hotchkiss KA, Suter C, Dudman NP, Szollosi J, Chesterman CN, Chong BH, Hogg PJ. Physical proximity and functional association of glycoprotein 1balpha and protein-disulfide isomerase on the platelet plasma membrane. J Biol Chem 2000; 275:9758-66.
44 Kroning H, Kahne T, Ittenson A, Franke A, Ansorge S. Thiol-proteindisulfide-oxidoreductase (proteindisulfide isomerase): a new plasma membrane constituent of mature human B lymphocytes. Scand J Immunol 1994; 39:346-50.
45 Fenouillet E, Barbouche R, Courageot J, Miquelis R. The catalytic activity of protein disulfide isomerase is involved in human immunodeficiency virus envelope-mediated membrane fusion after CD4 cell binding. J Infect Dis 2001; 183:744-52.
46 Donoghue N, Yam PT, Jiang XM, Hogg PJ. Presence of closely spaced protein thiols on the surface of mammalian cells. Protein Sci 2000; 9:2436-45.
47 Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000; 18:739-66.
48 Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997; 16:29-57.
49 Carini C, Fratazzi C. Detection of IgG subclasses with anti-IgE activity in patients with atopic diseases. Int Arch Allergy Appl Immunol 1992; 98:227-32.
50 Shakib F. The role of antiglobulins in IgG4-mediated allergic diseases. N Engl Reg Allergy Proc 1988; 9:35-42.
51 Rock B, Martins CR, Theofilopoulos AN et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (Fogo selvagem). N Engl J Med 1989; 320:1463-9.
52 Nagpal S, Namboodiri MSA, Subba R. IgG4 autoantibodies to DNA in systemic lupus erythematosus patients. Int Arch Allergy Appl Immunol 1991; 95:1-6.
53 Van Der Zee JS, Van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol 1986; 64:415-22.
54 Hagan P, Blumenthal UJ, Dunn D, Simpson AJG, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991; 349:243-5.
55 Kurniawan A, Yazdanbakhsh M, Van Ree R, Aalberse RC, Selkirk ME, Partono F, Maizels RM. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J Immunol 1993; 150:3941-50.
56 Rihet P, Demeure CE, Dessein AJ, Bourgois A. Strong serum inhibition of specific IgE correlated to competing IgG4, revealed by a new methodology in subjects from a S. mansoni endemic area. Eur J Immunol 1992; 22:2063-70.
57 Hussain R, Poindexter RW, Ottesen EA. Control of allergic reactivity in human filariasis: predominant localization of blocking antibody to the IgG4 subclass. J Immunol 1992; 148:2731-7.
58 Lessof MH, Sobotka AK, Lichtenstein LM. Protection against anaphylaxis in hymenoptera-sensitive patients by passive immunization. Monogr Allergy 1977; 12:253-6.
59 AAAI Board of Directors. Measurement of specific and nonspecific IgG4 levels as diagnostic and prognostic tests for clinical allergy. J Allergy Clin Immunol 1995; 95:652-4.
60 Bernstein IL, Storms WW. Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy Asthma and Immunology. Ann Allergy Asthma Immunol 1995; 75:543-625.
61 Aalberse RC, Van Milligen FJ, Van'T H, Stapel SO. Allergen-specific IgG4 in atopic disease. Allergy 1993; 48:559-69.
62 Mudde GC, Van Reijsen FC, Boland GJ, De Gast GC, Bruijnzeel PLB, Bruijnzeel-Koomen CAFM. Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. Immunology 1990; 69:335-41.
63 Mudde GC, Bheekha R, Bruijnzeel-Koomen CAFM. IgE-mediated antigen presentation. Allergy 1995; 50:193-9.
64 Van Der Heijden FL, Van Neerven RJJ, Van Katwijk M, Bos JD, Kapsenberg ML. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993; 150:3643-50.
65 Van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:2944-52.
66 Corper AL, Sohi MK, Bonagura VR et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997; 4:374-81.
|
Language: | English.
|
Document Type: | Review Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0019-2805
|
NLM Journal Code: | gh7, 0374672
|
Annotation(s) | |
|
|